United States Anesthesia Drugs Market & Forecast
United States Anesthesia Market is expected to be more than US$ 4 Billion by 2022. This growth is driven by increasing incidence of cardiovascular cases, growing old age population and rising number of urgent surgeries in United States. Private as well as public health insurers also help to boost this market as they consider anesthetic products in their reimbursement policy.
General Intravenous Anesthesia is the Leading Segments in the United States Anesthesia Market
General intravenous anesthesia is the leading segments in the United States Anesthesia Market. Propofol, Benzodiazepines Class, Fospropofol Disodium, Ketamine, Methohexital Sodium, Pentobarbital, Etomidate and Fentanyl are commonly used general intravenous anesthesia in the United States. Among these anesthesia, Propofol and Benzodiazepines Class are the leading anesthesia drugs which hold more than 75 percent combined market share in 2016.
Major Anesthesia Drug’s Manufacturers are continuously losing their Sales in United Sates
In the United States anesthesia drugs market several players are selling their products. Most of the anesthesia drugs sale are in generic form as it is available in the low cost. However all major drugs manufactures such as AstraZeneca, AbbVie , Endo Healthcare etc. anesthesia products sales are turning down continuously. Only Baxter International anesthesia drugs sales are growing in the United States market.
United States Anesthesia Drugs Market & Forecast is the 2nd edition report on United States Anesthesia Market published by Renub Research. This 127 page report with 55 Figures and 16 Tables provides a detailed analysis of local and general anesthesia drugs market, health insurers’ anesthesia reimbursement policies, eligibility criteria and reimbursement methods in United States. This report has been studied from 8 viewpoints.
1. United Sates Anesthesia Market
2. United Sates Anesthesia Drugs Share Analysis
3. General Anesthesia Market
4. Local Anesthesia Market
5. Anesthesia Reimbursement Policy by Health Insurance Companies (Private & Public)
6. Major Companies Anesthesia Sales
7. United States Anesthesia Market Drivers
8. United States Anesthesia Market Challenges
General Intravenous Anesthetic Drugs Market has been further divided into
1. Propofol Market (2011 – 2022)
2. Benzodiazepines Class (Diazepam and Midazolam) (2011 – 2022)
3. Fospropofol Disodium (2011 – 2022)
4. Ketamine (2011 – 2022)
5. Methohexital Sodium (2011 – 2022)
6. Pentobarbital (2011 – 2022)
7. Etomidate (2011 – 2022)
8. Fentanyl (2011 – 2022)
United States Local Anesthetic Market has been further divided into
1. Articane (2011 – 2022)
2. Bupivacaine (2011 – 2022)
3. Lidocaine (2011 – 2022)
4. Mepivacaine (2011 – 2022)
5. Prilocaine (2011 – 2022)
Key Players Sales in United States Anesthetic Drugs Market
1. Baxter International Inc (2011 – 2022)
2. Endo Health Solutions Inc (2011 – 2022)
3. AbbVie (2011 – 2022)
4. AstraZeneca (2011 – 2022)
This report provides the answer of following questions
General Intravenous Anesthesia is the Leading Segments in the United States Anesthesia Market
General intravenous anesthesia is the leading segments in the United States Anesthesia Market. Propofol, Benzodiazepines Class, Fospropofol Disodium, Ketamine, Methohexital Sodium, Pentobarbital, Etomidate and Fentanyl are commonly used general intravenous anesthesia in the United States. Among these anesthesia, Propofol and Benzodiazepines Class are the leading anesthesia drugs which hold more than 75 percent combined market share in 2016.
Major Anesthesia Drug’s Manufacturers are continuously losing their Sales in United Sates
In the United States anesthesia drugs market several players are selling their products. Most of the anesthesia drugs sale are in generic form as it is available in the low cost. However all major drugs manufactures such as AstraZeneca, AbbVie , Endo Healthcare etc. anesthesia products sales are turning down continuously. Only Baxter International anesthesia drugs sales are growing in the United States market.
United States Anesthesia Drugs Market & Forecast is the 2nd edition report on United States Anesthesia Market published by Renub Research. This 127 page report with 55 Figures and 16 Tables provides a detailed analysis of local and general anesthesia drugs market, health insurers’ anesthesia reimbursement policies, eligibility criteria and reimbursement methods in United States. This report has been studied from 8 viewpoints.
1. United Sates Anesthesia Market
2. United Sates Anesthesia Drugs Share Analysis
3. General Anesthesia Market
4. Local Anesthesia Market
5. Anesthesia Reimbursement Policy by Health Insurance Companies (Private & Public)
6. Major Companies Anesthesia Sales
7. United States Anesthesia Market Drivers
8. United States Anesthesia Market Challenges
General Intravenous Anesthetic Drugs Market has been further divided into
1. Propofol Market (2011 – 2022)
2. Benzodiazepines Class (Diazepam and Midazolam) (2011 – 2022)
3. Fospropofol Disodium (2011 – 2022)
4. Ketamine (2011 – 2022)
5. Methohexital Sodium (2011 – 2022)
6. Pentobarbital (2011 – 2022)
7. Etomidate (2011 – 2022)
8. Fentanyl (2011 – 2022)
United States Local Anesthetic Market has been further divided into
1. Articane (2011 – 2022)
2. Bupivacaine (2011 – 2022)
3. Lidocaine (2011 – 2022)
4. Mepivacaine (2011 – 2022)
5. Prilocaine (2011 – 2022)
Key Players Sales in United States Anesthetic Drugs Market
1. Baxter International Inc (2011 – 2022)
2. Endo Health Solutions Inc (2011 – 2022)
3. AbbVie (2011 – 2022)
4. AstraZeneca (2011 – 2022)
This report provides the answer of following questions
- Which one is the leading market (Local anesthesia or general Anesthesia) in the United States Anesthesia market?
- Which is the leading local anesthesia drug in United States Local Anesthesia Market?
- Which is the leading General anesthesia drug in United States General Anesthesia Market?
- What is the market size of each anesthesia drugs during 2011 – 2022?
- What is the reimbursement policy on anesthetic services in the United States?
- What are the anesthesia drugs sales situations in United States for key anesthesia players?
- What is the reimbursements policy in United States for Anesthesia by Private and Public Insurers
1 EXECUTIVE SUMMARY
2 UNITED STATES ANESTHESIA DRUGS MARKET (2011 – 2022)
3 UNITED STATES ANESTHESIA DRUGS MARKET SHARE & FORECAST (2011 – 2022)
3.1 United States Anesthesia Drugs Market Share & Forecast by Type (2011 – 2022)
3.2 United States General Intravenous Anesthesia Drugs Market Share & Forecast (2011 – 2022)
3.3 United States Local Anesthesia Drugs Market Share & Forecast (2011 – 2022)
3.4 United States Anesthesia Drugs Market Share & Forecast by Company (2011 – 2022)
4 BY TYPE – UNITED STATES ANESTHESIA DRUGS MARKET (2011 – 2022)
4.1 United States General Inhalation Anesthesia Drugs Market (2011 – 2022)
4.2 United States General Intravenous Anesthesia Drugs Market (2011 – 2022)
4.3 United States Local Anesthesia Drugs Market (2011 – 2022)
5 BY DRUGS – UNITED STATES GENERAL INTRAVENOUS ANESTHESIA DRUGS MARKET (2011 – 2022)
5.1 United States Propofol Market (2011 – 2022)
5.2 United States Benzodiazepines Class (Diazepam and Midazolam) Market (2011 – 2022)
5.3 United States Fospropofol Disodium Market (2011 – 2022)
5.4 United States Ketamine Market (2011 – 2022)
5.5 United States Methohexital Sodium Market (2011 – 2022)
5.6 United States Pentobarbital Market (2011 – 2022)
5.7 United States Etomidate Market (2011 – 2022)
5.8 United States Fentanyl Market (2011 – 2022)
6 BY DRUGS – UNITED STATES LOCAL ANESTHESIA DRUGS MARKET (2011 – 2022)
6.1 United States Articaine Market (2011 – 2022)
6.2 United States Bupivacaine Market (2011 – 2022)
6.3 United States Lidocaine Market (2011 – 2022)
6.4 United States Mepivacaine Market (2011 – 2022)
6.5 United States Prilocaine Market (2011 – 2022)
7 KEY PLAYERS PROFILE IN UNITED STATES ANESTHESIA DRUGS MARKET
7.1 Baxter International Inc. Anesthesia Drugs Sales & Forecast (2011 – 2022)
7.2 Endo Health Solutions Inc. Anesthesia Drugs Sales & Forecast (2011 – 2022)
7.3 AbbVie Anesthesia Drugs Sales & Forecast (2011 – 2022)
7.4 AstraZeneca Anesthetic Drugs Sales (2009 – 2011)
8 UNITED STATES ANESTHESIA MARKET MERGER & ACQUISITION (M&A)
9 UNITED STATES ANESTHESIA REIMBURSEMENT POLICY - PRIVATE HEALTH INSURANCE PROVIDERS
9.1 Aetna International
9.2 Coventry Health Care
9.3 Anthem Blue Cross and Blue Shield
9.4 Blue Cross and Blue Shield of Texas
9.5 UnitedHealthcare
9.5.1 State Exceptions
10 UNITED STATES ANESTHESIA REIMBURSEMENT POLICY – PUBLIC HEALTH INSURANCE PROVIDERS
10.1 Medicare
10.2 MDWise
11 UNITED STATES ANESTHESIA DRUGS MARKET – GROWTH DRIVERS
11.1 Growing Demand for Anesthesia Service
11.2 Rise in Ageing Population & Prevalence of Cardiovascular Disease in United States
11.2.1 Rise in Ageing Population
12 UNITED STATES ANESTHESIA DRUGS MARKET – CHALLENGES
12.1 Un-match Anesthesia Providers in United States
12.2 Shortage of Anesthesia Drugs in United States
2 UNITED STATES ANESTHESIA DRUGS MARKET (2011 – 2022)
3 UNITED STATES ANESTHESIA DRUGS MARKET SHARE & FORECAST (2011 – 2022)
3.1 United States Anesthesia Drugs Market Share & Forecast by Type (2011 – 2022)
3.2 United States General Intravenous Anesthesia Drugs Market Share & Forecast (2011 – 2022)
3.3 United States Local Anesthesia Drugs Market Share & Forecast (2011 – 2022)
3.4 United States Anesthesia Drugs Market Share & Forecast by Company (2011 – 2022)
4 BY TYPE – UNITED STATES ANESTHESIA DRUGS MARKET (2011 – 2022)
4.1 United States General Inhalation Anesthesia Drugs Market (2011 – 2022)
4.2 United States General Intravenous Anesthesia Drugs Market (2011 – 2022)
4.3 United States Local Anesthesia Drugs Market (2011 – 2022)
5 BY DRUGS – UNITED STATES GENERAL INTRAVENOUS ANESTHESIA DRUGS MARKET (2011 – 2022)
5.1 United States Propofol Market (2011 – 2022)
5.2 United States Benzodiazepines Class (Diazepam and Midazolam) Market (2011 – 2022)
5.3 United States Fospropofol Disodium Market (2011 – 2022)
5.4 United States Ketamine Market (2011 – 2022)
5.5 United States Methohexital Sodium Market (2011 – 2022)
5.6 United States Pentobarbital Market (2011 – 2022)
5.7 United States Etomidate Market (2011 – 2022)
5.8 United States Fentanyl Market (2011 – 2022)
6 BY DRUGS – UNITED STATES LOCAL ANESTHESIA DRUGS MARKET (2011 – 2022)
6.1 United States Articaine Market (2011 – 2022)
6.2 United States Bupivacaine Market (2011 – 2022)
6.3 United States Lidocaine Market (2011 – 2022)
6.4 United States Mepivacaine Market (2011 – 2022)
6.5 United States Prilocaine Market (2011 – 2022)
7 KEY PLAYERS PROFILE IN UNITED STATES ANESTHESIA DRUGS MARKET
7.1 Baxter International Inc. Anesthesia Drugs Sales & Forecast (2011 – 2022)
7.2 Endo Health Solutions Inc. Anesthesia Drugs Sales & Forecast (2011 – 2022)
7.3 AbbVie Anesthesia Drugs Sales & Forecast (2011 – 2022)
7.4 AstraZeneca Anesthetic Drugs Sales (2009 – 2011)
8 UNITED STATES ANESTHESIA MARKET MERGER & ACQUISITION (M&A)
9 UNITED STATES ANESTHESIA REIMBURSEMENT POLICY - PRIVATE HEALTH INSURANCE PROVIDERS
9.1 Aetna International
9.2 Coventry Health Care
9.3 Anthem Blue Cross and Blue Shield
9.4 Blue Cross and Blue Shield of Texas
9.5 UnitedHealthcare
9.5.1 State Exceptions
10 UNITED STATES ANESTHESIA REIMBURSEMENT POLICY – PUBLIC HEALTH INSURANCE PROVIDERS
10.1 Medicare
10.2 MDWise
11 UNITED STATES ANESTHESIA DRUGS MARKET – GROWTH DRIVERS
11.1 Growing Demand for Anesthesia Service
11.2 Rise in Ageing Population & Prevalence of Cardiovascular Disease in United States
11.2.1 Rise in Ageing Population
12 UNITED STATES ANESTHESIA DRUGS MARKET – CHALLENGES
12.1 Un-match Anesthesia Providers in United States
12.2 Shortage of Anesthesia Drugs in United States
LIST OF FIGURES:
Figure 2‑1: United States – Anesthesia Drugs Market (Million US$), 2011 – 2016
Figure 2‑2: United States – Forecast for Anesthesia Drugs Market (Million US$), 2017 – 2022
Figure 3‑1: United States – Anesthesia Drugs Market Share by Type (Percent), 2011 – 2016
Figure 3‑2: United States – Forecast for Anesthesia Drugs Market Share by Type (Percent), 2017 – 2022
Figure 3‑3: United States – General Intravenous Anesthesia Drugs Market Share (Percent), 2011 – 2016
Figure 3‑4: United States – Forecast for General Intravenous Anesthesia Drugs Market Share (Percent), 2017 – 2022
Figure 3‑5: United States – Local Anesthesia Drugs Market Share (Percent), 2011 – 2016
Figure 3‑6: United States – Forecast for Local Anesthesia Drugs Market Share (Percent), 2017 – 2022
Figure 3‑7: United States – Anesthesia Drugs Market Share by Company (Percent), 2011 – 2016
Figure 3‑8: United States – Forecast for Anesthesia Drugs Market Share by Company (Percent), 2017 – 2022
Figure 4‑1: United States – General Inhalation Anesthesia Drugs Market (Million US$), 2011-2016
Figure 4‑2: United States – Forecast for General Inhalation Anesthesia Drugs Market (Million US$), 2017 – 2022
Figure 4‑3: United States – General Intravenous Anesthesia Drugs Market (Million US$), 2011 – 2016
Figure 4‑4: United States – Forecast for General Intravenous Anesthesia Drugs Market (Million US$), 2017 – 2022
Figure 4‑5: United States – Local Anesthesia Drugs Market (Million US$), 2011-2016
Figure 4‑6: United States – Forecast for Local Anesthesia Drugs Market (Million US$), 2017 – 2022
Figure 5‑1: United States – Propofol Market (Million US$), 2011 – 2016
Figure 5‑2: United States – Forecast for Propofol Market (Million US$), 2017 – 2022
Figure 5‑3: United States – Benzodiazepines Class Market (Million US$), 2011 – 2016
Figure 5‑4: United States – Forecast for Benzodiazepines Class Market (Million US$), 2017 – 2022
Figure 5‑5: United States – Fospropofol Disodium Market (Million US$), 2011 – 2016
Figure 5‑6: United States – Forecast for Fospropofol Disodium Market (Million US$), 2017 – 2022
Figure 5‑7: United States – Ketamine Market (Million US$), 2011 – 2016
Figure 5‑8: United States – Forecast for Ketamine Market (Million US$), 2017 – 2022
Figure 5‑9: United States – Methohexital Sodium Market (Million US$), 2011 – 2016
Figure 5‑10: United States – Forecast for Methohexital Sodium Market (Million US$), 2017 – 2022
Figure 5‑11: United States – Pentobarbital Market (Million US$), 2011 – 2016
Figure 5‑12: United States – Forecast for Pentobarbital Market (Million US$), 2017 – 2022
Figure 5‑13: United States – Etomidate Market (Million US$), 2011 – 2016
Figure 5‑14: United States – Forecast for Etomidate Market (Million US$), 2017 – 2022
Figure 5‑15: United States – Fentanyl Market (Million US$), 2011 – 2016
Figure 5‑16: United States – Forecast for Fentanyl Market (Million US$), 2017 – 2022
Figure 6‑1: United States – Articaine Market (Million US$), 2011-2016
Figure 6‑2: United States – Forecast for Articane Market (Million US$), 2017 – 2022
Figure 6‑3: United States – Bupivacaine Market (Million US$), 2011-2016
Figure 6‑4: United States – Forecast for Bupivacaine Market (Million US$), 2017 – 2022
Figure 6‑5: United States – Lidocaine Market (Million US$), 2011-2016
Figure 6‑6: United States – Forecast for Lidocaine Market (Million US$), 2017 – 2022
Figure 6‑7: United States – Mepivacaine Market (Million US$), 2011-2016
Figure 6‑8: United States – Forecast for Mepivacaine Market (Million US$), 2017 – 2022
Figure 6‑9: United States – Prilocaine Market (Million US$), 2011-2016
Figure 6‑10: United States – Forecast for Prilocaine Market (Million US$), 2017 – 2022
Figure 7‑1: United States – Baxter International Anesthesia Drugs Sales (Million US$), 2011-2016
Figure 7‑2: United States – Forecast for Baxter International Anesthesia Drugs Sales (Million US$), 2017 – 2022
Figure 7‑3: United States – Endo Health Solutions Anesthesia Drugs Sales (Million US$), 2011-2016
Figure 7‑4: United States – Forecast for Endo Health Solutions Anesthesia Drugs Sales (Million US$), 2017 – 2022
Figure 7‑5: United States – AbbVie Anesthesia Drugs Sales (Million US$), 2011 - 2016
Figure 7‑6: United States – Forecast for AbbVie Anesthesia Drugs Sales (Million US$), 2017 – 2022
Figure 7‑7: United States – AstraZeneca Anesthesia Drugs Sales (Million US$), 2009 – 2011
Figure 11‑1: United States – Cosmetic Procedures (Number), 1997, 2012-2013, 2015-2016
Figure 11‑3: United States – Ageing Population by Age Group (Thousand), 2012 – 2016
Figure 12‑1: United States – By Region Availability of Anesthesia Specialists (Percent), 2010
Figure 12‑2: United States – By States Availability of Anesthesia Specialists (Percent), 2010
Figure 12‑3: United States – Drugs Shortage (Number), 2001-2015
Figure 12‑4: United States – Anesthesia Drugs Shortage with the Highest Frequency (Percent), 2012
Figure 2‑1: United States – Anesthesia Drugs Market (Million US$), 2011 – 2016
Figure 2‑2: United States – Forecast for Anesthesia Drugs Market (Million US$), 2017 – 2022
Figure 3‑1: United States – Anesthesia Drugs Market Share by Type (Percent), 2011 – 2016
Figure 3‑2: United States – Forecast for Anesthesia Drugs Market Share by Type (Percent), 2017 – 2022
Figure 3‑3: United States – General Intravenous Anesthesia Drugs Market Share (Percent), 2011 – 2016
Figure 3‑4: United States – Forecast for General Intravenous Anesthesia Drugs Market Share (Percent), 2017 – 2022
Figure 3‑5: United States – Local Anesthesia Drugs Market Share (Percent), 2011 – 2016
Figure 3‑6: United States – Forecast for Local Anesthesia Drugs Market Share (Percent), 2017 – 2022
Figure 3‑7: United States – Anesthesia Drugs Market Share by Company (Percent), 2011 – 2016
Figure 3‑8: United States – Forecast for Anesthesia Drugs Market Share by Company (Percent), 2017 – 2022
Figure 4‑1: United States – General Inhalation Anesthesia Drugs Market (Million US$), 2011-2016
Figure 4‑2: United States – Forecast for General Inhalation Anesthesia Drugs Market (Million US$), 2017 – 2022
Figure 4‑3: United States – General Intravenous Anesthesia Drugs Market (Million US$), 2011 – 2016
Figure 4‑4: United States – Forecast for General Intravenous Anesthesia Drugs Market (Million US$), 2017 – 2022
Figure 4‑5: United States – Local Anesthesia Drugs Market (Million US$), 2011-2016
Figure 4‑6: United States – Forecast for Local Anesthesia Drugs Market (Million US$), 2017 – 2022
Figure 5‑1: United States – Propofol Market (Million US$), 2011 – 2016
Figure 5‑2: United States – Forecast for Propofol Market (Million US$), 2017 – 2022
Figure 5‑3: United States – Benzodiazepines Class Market (Million US$), 2011 – 2016
Figure 5‑4: United States – Forecast for Benzodiazepines Class Market (Million US$), 2017 – 2022
Figure 5‑5: United States – Fospropofol Disodium Market (Million US$), 2011 – 2016
Figure 5‑6: United States – Forecast for Fospropofol Disodium Market (Million US$), 2017 – 2022
Figure 5‑7: United States – Ketamine Market (Million US$), 2011 – 2016
Figure 5‑8: United States – Forecast for Ketamine Market (Million US$), 2017 – 2022
Figure 5‑9: United States – Methohexital Sodium Market (Million US$), 2011 – 2016
Figure 5‑10: United States – Forecast for Methohexital Sodium Market (Million US$), 2017 – 2022
Figure 5‑11: United States – Pentobarbital Market (Million US$), 2011 – 2016
Figure 5‑12: United States – Forecast for Pentobarbital Market (Million US$), 2017 – 2022
Figure 5‑13: United States – Etomidate Market (Million US$), 2011 – 2016
Figure 5‑14: United States – Forecast for Etomidate Market (Million US$), 2017 – 2022
Figure 5‑15: United States – Fentanyl Market (Million US$), 2011 – 2016
Figure 5‑16: United States – Forecast for Fentanyl Market (Million US$), 2017 – 2022
Figure 6‑1: United States – Articaine Market (Million US$), 2011-2016
Figure 6‑2: United States – Forecast for Articane Market (Million US$), 2017 – 2022
Figure 6‑3: United States – Bupivacaine Market (Million US$), 2011-2016
Figure 6‑4: United States – Forecast for Bupivacaine Market (Million US$), 2017 – 2022
Figure 6‑5: United States – Lidocaine Market (Million US$), 2011-2016
Figure 6‑6: United States – Forecast for Lidocaine Market (Million US$), 2017 – 2022
Figure 6‑7: United States – Mepivacaine Market (Million US$), 2011-2016
Figure 6‑8: United States – Forecast for Mepivacaine Market (Million US$), 2017 – 2022
Figure 6‑9: United States – Prilocaine Market (Million US$), 2011-2016
Figure 6‑10: United States – Forecast for Prilocaine Market (Million US$), 2017 – 2022
Figure 7‑1: United States – Baxter International Anesthesia Drugs Sales (Million US$), 2011-2016
Figure 7‑2: United States – Forecast for Baxter International Anesthesia Drugs Sales (Million US$), 2017 – 2022
Figure 7‑3: United States – Endo Health Solutions Anesthesia Drugs Sales (Million US$), 2011-2016
Figure 7‑4: United States – Forecast for Endo Health Solutions Anesthesia Drugs Sales (Million US$), 2017 – 2022
Figure 7‑5: United States – AbbVie Anesthesia Drugs Sales (Million US$), 2011 - 2016
Figure 7‑6: United States – Forecast for AbbVie Anesthesia Drugs Sales (Million US$), 2017 – 2022
Figure 7‑7: United States – AstraZeneca Anesthesia Drugs Sales (Million US$), 2009 – 2011
Figure 11‑1: United States – Cosmetic Procedures (Number), 1997, 2012-2013, 2015-2016
Figure 11‑3: United States – Ageing Population by Age Group (Thousand), 2012 – 2016
Figure 12‑1: United States – By Region Availability of Anesthesia Specialists (Percent), 2010
Figure 12‑2: United States – By States Availability of Anesthesia Specialists (Percent), 2010
Figure 12‑3: United States – Drugs Shortage (Number), 2001-2015
Figure 12‑4: United States – Anesthesia Drugs Shortage with the Highest Frequency (Percent), 2012
LIST OF TABLES:
Table 8‑1: United States – Anesthesia Market Merger & Acquisitions (M&A), Jan 2016 – March 2017
Table 9‑1: Coventry Health Care - Anesthesia Modifiers, 2016
Table 9‑2: Blue Cross and Blue Shield of Texas - Physical Status Modifiers, 2017
Table 9‑3: Blue Cross and Blue Shield of Texas - Qualifying Circumstances, 2017
Table 9‑4: Blue Cross and Blue Shield of Texas - Modifier Information Billed by an Anesthesiologist, 2017
Table 9‑5: Blue Cross and Blue Shield of Texas - Modifier Information Billed by a CRNA, 2017
Table 9‑6: Blue Cross and Blue Shield of Texas - Anesthesia Modifier Reimbursement
Table 9‑7: UnitedHealthcare Community – Modifiers, 2017
Table 10‑1: Medicare - Reimbursement Formulas
Table 10‑2: Medicare - General and Monitored Anesthesia Care
Table 10‑3: Medicare - Anesthesia Modifiers, 2017
Table 10‑4: MDwise –Type of Service & PA Requirement
Table 10‑5: MDwise - Anesthesia Time Table, 2017
Table 10‑6: MDwise - Qualifying Circumstances, 2017
Table 10‑7: MDwise - Status Modifiers, 2017
Table 11‑1: United States – Cardiovascular Disease Prevalence (Percent), 2010,2015,2020,2025, 2030
Table 8‑1: United States – Anesthesia Market Merger & Acquisitions (M&A), Jan 2016 – March 2017
Table 9‑1: Coventry Health Care - Anesthesia Modifiers, 2016
Table 9‑2: Blue Cross and Blue Shield of Texas - Physical Status Modifiers, 2017
Table 9‑3: Blue Cross and Blue Shield of Texas - Qualifying Circumstances, 2017
Table 9‑4: Blue Cross and Blue Shield of Texas - Modifier Information Billed by an Anesthesiologist, 2017
Table 9‑5: Blue Cross and Blue Shield of Texas - Modifier Information Billed by a CRNA, 2017
Table 9‑6: Blue Cross and Blue Shield of Texas - Anesthesia Modifier Reimbursement
Table 9‑7: UnitedHealthcare Community – Modifiers, 2017
Table 10‑1: Medicare - Reimbursement Formulas
Table 10‑2: Medicare - General and Monitored Anesthesia Care
Table 10‑3: Medicare - Anesthesia Modifiers, 2017
Table 10‑4: MDwise –Type of Service & PA Requirement
Table 10‑5: MDwise - Anesthesia Time Table, 2017
Table 10‑6: MDwise - Qualifying Circumstances, 2017
Table 10‑7: MDwise - Status Modifiers, 2017
Table 11‑1: United States – Cardiovascular Disease Prevalence (Percent), 2010,2015,2020,2025, 2030
